References
-
1
Amiaz R, Fostick L, Gershon A. et al .
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.
Eur Neuropsycho-pharmacol.
2008;
18
455-461
-
2
Barbarich N.
Is there a common mechanism of serotonin dysregulation in anorexia nervosa and obsessive-compulsive disorder?.
Eat Weight Disord.
2002;
7
221-231
-
3
Bosanac P, Norman T, Burrows G. et al .
Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?.
J Aust N Z J Psychiatry.
2005;
39
146-153
-
4
Daws LC, White JM.
Regulation of opioid receptors by opioid antagonists: implications for rapid opioid detoxification.
Addiction Biology.
1999;
4
391-397
-
5
Denys D, Zohar J, Westenberg HG.
The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.
J Clin Psychiatry.
2004;
65
((Suppl 14))
11-17
-
6
Hamidi A, Jahanguiri B, Nasr Esfahani M. et al .
Naltrexone in obsessive-compulsive disorder: an open-label trial.
Iranian J Psychiatr Behav Sci.
2007;
1
16-21
-
7
Hsu LK, Kaye W, Weltsin T.
Are the eating disorders related to obsessive-compulsive disorder?.
Int J Eat Disord.
1993;
14
305-318
-
8
Insel TR, Pickar D.
Naloxone administration in obsessive-compulsive disorder: report of two cases.
Am J Psychiatry.
1983;
140
1219-1220
-
9
Keuler DJ, Altemus M, Michelson D. et al .
Behavioral effects of naloxone infusion in obsessive-compulsive disorder.
Biol Psychiatry.
1996;
40
154-156
-
10
Kruger S, Kennedy SH.
Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder.
J Psychiatry Neurosci.
2000;
25
497-508
-
11
Luby ED, Marrazzi MA, Kinzie J.
Treatment of chronic anorexia nervosa with opiate blockade.
J Clin Psychopharmacol.
1987;
7
52-53
-
12
Marrazzi MA, Bacon JP, Kinzie J. et al .
Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa.
Int Clin Psychopharmacol.
1995;
10
163-172
-
13
Marazzi MA, Luby ED, Kinzie J. et al .
Endogenous codeine and morphine in anorexia and bulimia nervosa.
Life Sci.
1997;
60
1741-1747
-
14
MacElroy SL, Phillips KA, Keck Jr PE.
Obsessive-compulsive spectrum disorder.
J Clin Psychiatry.
1994;
55
((Suppl))
33-51
, discussion 52–53
-
15
Modesto-Lowe V, Kirk J Van.
Clinical uses of naltrexone: a review of the evidence.
Exp Clin Psychopharmacol.
2002;
10
213-227
-
16
Sandyk R.
Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome.
Int J Neurosci.
1987;
35
93-94
-
17
Tomkins DM, Sellers EM.
Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence.
Can Med Assoc.
2001;
164
817-821
-
18
Warneke L.
A possible new treatment approach to obsessive-compulsive disorder.
Can J Psychiatry.
1997;
42
667-668
-
19
Wockel L, Koch S, Stadler C. et al .
Serotonin-induced platelet intracellular Ca2+ response in patients with anorexia nervosa.
Pharmacopsychiatry.
2008;
41
W10-16
Correspondence
K. GadeMD
Department of Psychiatry and Psychotherapy
University of Göttingen
von-Siebold-Str. 5
37075 Göttingen
Germany
Phone: +49 551 396 610
Fax: +49 551 399 337
Email: katrin_gade@web.de
